

DEC 18 2006

## 3.0 510(k) Summary

Page 1 of 1

- Sponsor:** Synthes (USA)  
1301 Goshen Parkway  
West Chester, PA 19380  
(610) 719-5000
- Device Name:** Synthes (USA) Modular Mini Fragment LCP System
- Classification:** 21 CFR 888.3030: Single/multiple component metallic bone fixation appliances and accessories  
21 CFR 888.3040: Smooth or threaded metallic bone fixation fastener
- Predicate Devices:** Synthes Stainless Steel Modular Hand System  
Synthes Modular Foot System  
Synthes Modular Foot System – 2.7 mm Module
- Device Description:** The Synthes (USA) Modular Mini Fragment LCP System includes 2.0, 2.4, and 2.7 mm size implants. The system incorporates a series of locking compression plates and screws of varying lengths, thicknesses, and configurations including straight, condylar, T-, Y-, adaption plates. These plates are attached to bone via 2.0, 2.4, and 2.7 mm cortex and locking screws.
- Intended Use:** The Synthes (USA) Modular Mini Fragment LCP System is intended for fixation of fractures, osteotomies, nonunions, replantations, and fusions of small bones and small bone fragments, particularly in osteopenic bone. Examples include, but are not limited to, the hand, wrist, foot, and ankle.
- Substantial Equivalence:** Information presented supports substantial equivalence.



Food and Drug Administration  
9200 Corporate Boulevard  
Rockville MD 20850

Synthes (USA)  
% Deborah L. Jackson, RAC  
Regulatory Affairs Specialist  
1301 Goshen Parkway  
West Chester, Pennsylvania 19380

DEC 18 2006

Re: K063049

Trade/Device Name: Synthes (USA) Modular Mini Fragment LCP System  
Regulation Number: 21 CFR 888.3030  
Regulation Name: Single/multiple component metallic bone fixation appliances and accessories  
Regulatory Class: Class II  
Product Code: HRS  
Dated: October 3, 2006  
Received: October 6, 2006

Dear Dr. Clark

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.


Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

Page 2 – Deborah L. Jackson, RAC

This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of Compliance at (240) 276-0210 Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (240) 276-3150 or at its Internet address <http://www.fda.gov/cdrh/industry/support/index.html>.

Sincerely yours,

A handwritten signature in black ink, appearing to read "For Mark N. Melkerson". To the right of the signature, there are several handwritten initials and dates: "RAC", "MD", "10/20", and "D.R.". The signature is written over a horizontal line.

Mark N. Melkerson  
Director  
Division of General, Restorative  
and Neurological Devices  
Office of Device Evaluation  
Center for Devices and  
Radiological Health

Enclosure

**2.0 Indications for Use**

510(k) Number (if known): \_\_\_\_\_

Device Name: Synthes (USA) Modular Mini Fragment LCP System

Indications for Use: The Synthes (USA) Modular Mini Fragment LCP System is intended for fixation of fractures, osteotomies, nonunions, replantations, and fusions of small bones and small bone fragments, particularly in osteopenic bone. Examples include, but are not limited to, the hand, wrist, foot, and ankle.

Prescription Use   X   AND/OR Over-The-Counter Use \_\_\_\_\_  
(Per 21 CFR 801.109) (21 CFR 807 Subpart C)

(PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON ANOTHER PAGE IF NEEDED)

---

Concurrence of CDRH, Office of Device Evaluation (ODE)



**(Division Sign-Off)**  
**Division of General, Restorative,  
and Neurological Devices**

510(k) Number   1063049